FDA approves blood test to guide breast cancer therapy

Ella Jeffries / beckershospitalreview - The FDA has approved a companion diagnostic from Guardant Health to identify patients eligible for treatment with a targeted therapy developed by Pfizer and Arvinas. The blood-based test detects ESR1 mutations in patients with estrogen receptor-positive, …

AI Summary: The FDA approved a blood‑based test to help guide breast cancer treatment selection, authorizing a diagnostic that identifies patients more likely to benefit from specific therapies. The move could reduce unnecessary treatments and sharpen precision oncology, though broad clinical adoption will depend on further validation, payer coverage and clinician trust.

• ESMO Breast highlights and expert commentary (4)
• FDA clearances reshape diagnostics and therapies (3)
• Liquid biopsy, mutations and treatment resistance (4)
• All Other Stories

ESMO Breast highlights and expert commentary

FDA clearances reshape diagnostics and therapies

Liquid biopsy, mutations and treatment resistance

All Other Stories